Lumos Diagnostics Holdings (ASX:LDX) EBITDA Margin % : -18.40% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lumos Diagnostics Holdings's EBITDA for the six months ended in Dec. 2024 was A$-1.83 Mil. Lumos Diagnostics Holdings's Revenue for the six months ended in Dec. 2024 was A$9.96 Mil. Therefore, Lumos Diagnostics Holdings's EBITDA margin for the quarter that ended in Dec. 2024 was -18.40%.

Lumos Diagnostics Holdings EBITDA Margin % Historical Data

The historical data trend for Lumos Diagnostics Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings EBITDA Margin % Chart

Lumos Diagnostics Holdings Annual Data

Trend

Jun22

Jun23

Jun24

EBITDA Margin %

-367.41

-46.79

-48.84

Lumos Diagnostics Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial			-85.36	-10.78	-157.74	-12.83	-18.40

Competitive Comparison of Lumos Diagnostics Holdings's EBITDA Margin %

For the Medical Devices subindustry, Lumos Diagnostics Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's EBITDA Margin % falls into.

Lumos Diagnostics Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lumos Diagnostics Holdings's EBITDA Margin % for the fiscal year that ended in Jun. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-8.187	/	16.763
	=	-48.84 %

Lumos Diagnostics Holdings's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-1.832	/	9.957
	=	-18.40 %

Lumos Diagnostics Holdings (ASX:LDX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lumos Diagnostics Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

LDXHF:USA

Address

2724 Loker Avenue West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.

Lumos Diagnostics Holdings Headlines

No Headlines